| Followers | 2543 |
| Posts | 250731 |
| Boards Moderated | 34 |
| Alias Born | 05/06/2014 |
Tuesday, July 25, 2017 9:20:24 PM
$PMCB PharmaCyte Biotech and the FDA have agreed that the next step is to submit the IND for the upcoming trial in LAPC. The company has wisely chosen, imho, to refrain from predicting when the IND will be filed.
http://ir.pharmacytebiotech.com/press-releases/detail/137/pharmacyte-biotech-ceo-addresses-ind-submission-questions
The IND will be submitted.
Personally, I think the IND will be submitted in Sept. '17 and the trial will begin in Oct. '17. Regardless, I will continue to accumulate if the trial begins in Oct. '17, Nov. '17, Dec. '17, etc; the longer it takes the more shares I will have when the trial begins. Meanwhile, we've attracted yet another institutional investor.
I will continue to hold indefinitely, and accumulate once per week as I've done for over the past three years, until the upcoming trial in LAPC begins. I intend to hold more than half my position into the diabetes trials and/or buyout. The pc treatment is what had originally attracted my attention. The diabetes treatment is why I'm investing for the long haul.
Keep your eye on the prize
The top three insulin producers know the technology exists to eliminate the need for insulin, and that technology is being forwarded at a rigorous and unprecedented pace, hence their plundering of the insulin market:
https://www.nytimes.com/2017/01/30/health/drugmakers-lawsuit-insulin-drugs.html?_r=0
http://www.businessinsider.com/sanofi-novo-nordisk-lilly-named-in-class-action-insulin-lawsuit-2017-1
PharmaCyte Biotech's International Diabetes Consortium is conducting multiple pre-clinical studies, concurrently, to significantly reduce the time it takes to get their patented Melligen cell/Cell-in-a-Box® combo to treat diabetes into human clinical trials. PharmaCyte's diabetes treatment will eliminate the need for insulin, effectively curing both type 1 and type 2 diabetes, without the use of an internal/external or subcutaneous device of any kind - no other diabetes treatment in existence, to my knowledge, can claim that.
http://ir.pharmacytebiotech.com/press-releases/detail/137/pharmacyte-biotech-ceo-addresses-ind-submission-questions
The IND will be submitted.
Personally, I think the IND will be submitted in Sept. '17 and the trial will begin in Oct. '17. Regardless, I will continue to accumulate if the trial begins in Oct. '17, Nov. '17, Dec. '17, etc; the longer it takes the more shares I will have when the trial begins. Meanwhile, we've attracted yet another institutional investor.
I will continue to hold indefinitely, and accumulate once per week as I've done for over the past three years, until the upcoming trial in LAPC begins. I intend to hold more than half my position into the diabetes trials and/or buyout. The pc treatment is what had originally attracted my attention. The diabetes treatment is why I'm investing for the long haul.
Keep your eye on the prize
The top three insulin producers know the technology exists to eliminate the need for insulin, and that technology is being forwarded at a rigorous and unprecedented pace, hence their plundering of the insulin market:
https://www.nytimes.com/2017/01/30/health/drugmakers-lawsuit-insulin-drugs.html?_r=0
http://www.businessinsider.com/sanofi-novo-nordisk-lilly-named-in-class-action-insulin-lawsuit-2017-1
PharmaCyte Biotech's International Diabetes Consortium is conducting multiple pre-clinical studies, concurrently, to significantly reduce the time it takes to get their patented Melligen cell/Cell-in-a-Box® combo to treat diabetes into human clinical trials. PharmaCyte's diabetes treatment will eliminate the need for insulin, effectively curing both type 1 and type 2 diabetes, without the use of an internal/external or subcutaneous device of any kind - no other diabetes treatment in existence, to my knowledge, can claim that.
investorshub.advfn.com/$Pistol-Pete$-$Mick$-&-Friends-Stock-Picks-29568/
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
